Secondary Logo

Journal Logo


Hepatitis delta in HIV-infected individuals in Europe

Soriano, Vincenta; Grint, Danielb; d’Arminio Monforte, Antonellac; Horban, Andrzejd; Leen, Clifforde; Poveda, Evaa; Antunes, Franciscof; de Wit, Stephaneg; Lundgren, Jensh,i; Rockstroh, Juergenj; Peters, Larsh

Author Information
doi: 10.1097/QAD.0b013e32834babb3
  • Free



Hepatitis delta virus (HDV) is a defective subviral pathogen that requires the hepatitis B virus (HBV) surface antigen (HBsAg) to be infective. Delta hepatitis is the most aggressive form of chronic viral hepatitis in humans [1]. The virus has a small (1.7 Kb) single-stranded, circular RNA genome surrounded by two antigens, a small 24-kDa delta antigen (HDAg) and a bigger 27-kDa HDAg. The complete viral particle includes the RNA molecule coupled by delta antigens and coated by an external lipid layer in which HBsAg is incorporated and functions as envelope protein [2].

Around 15–20 million people are infected with HDV worldwide which overall represents 5% of individuals with chronic hepatitis B [3]. Endemic areas have been found in Mediterranean countries, eastern Europe, Middle East, central Asia, central Africa and the Amazonian region, although it is uncommon in northern Europe and North America [4,5]. The virus is transmitted sexually and through parenteral exposure; outbreaks have been reported among intravenous drug users [6]. Given shared routes of transmission, HIV-infected persons are at higher risk for acquiring HDV. However, information about the prevalence, epidemiology, virological profile and natural history of hepatitis delta in HIV-infected patients is scarce.

Patients and methods

Study population

EuroSIDA is a prospective study of 16 597 HIV-1-infected patients enrolled at 93 centres across Europe, Israel and Argentina; further details have been reported elsewhere [7]. Briefly, for each cohort the centres provide data on consecutive patients seen at the outpatient clinics beginning in May 1994 until a predefined number of patients enrol from each site. To date, eight cohorts of patients have been recruited. Data is collected prospectively at clinical sites and is extracted and sent to the coordinating centre at 6 monthly intervals. For cohorts I–III, eligible patients were those who had had a CD4 cell count less than 500 cells/μl during the previous 4 months. The CD4 cell count restriction was removed for cohorts IV–VII. At recruitment, in addition to demographic and clinical information, a complete hepatitis virological profile and antiretroviral treatment history is obtained, together with the most recent CD4 cell count and plasma HIV-RNA measurements. At each follow-up visit, details on all biochemistry, CD4 cell counts and plasma HIV-RNA values measured since the last follow-up visit are extracted, as are the dates of starting and stopping each antiretroviral drug received and the use of drugs for prophylaxis against opportunistic infections. The dates of diagnosis of all AIDS-defining illnesses, non-AIDS-defining malignancies and other serious infections are also recorded.

The delta substudy was carried out with analyses including follow-up to March 2011 and was focused on 1319 (7.9%) individuals that have ever reported as serum HBsAg-positive. At last follow-up, 1084 (6.5%) of them were HBsAg-positive. The main characteristics of the HBsAg-positive population in EuroSIDA have been reported previously [8,9].

Viral hepatitis markers

Serum HBV-DNA was measured using the bDNA assay v3.0 (Siemens, Barcelona, Spain). HBV genotyping was performed using a hybridization technique (InnoLIPA, Siemens) and/or population sequencing (HBV genotyping kit, Siemens).

HDV viral markers could be examined on 422 of the HBsAg-positive individuals for whom stored sera were available at the time they were HBsAg-positive. Anti-HDV immunoglobulin G was assessed using a commercial enzyme immunoassay (EIA) (Radim, Madrid, Spain). Serum HDV-RNA was quantified using a real-time PCR method which has a detection HDV-RNA limit of 10 copies/ml [10].

Statistical analysis

Characteristics of patients were compared using χ2-tests for categorical variables and nonparametric Wilcoxon or Kruskall–Wallis tests for continuous variables. Baseline was defined as the date of the serum sample. Logistic regression, using forward selection with entry criteria of P value less than 0.1, was used to identify which factors were associated with anti-HDV antibody reactivity in the study population. Multivariate Poisson regression modelling was used in time to event analyses to identify which factors were associated with progression to the clinical endpoints: death; AIDS; AIDS or death; and liver-related death (LRD). All data were analysed using SAS version 9.2 (Statistical Analysis Software, Cary, North Carolina, USA).


A total of 61 of 422 HBsAg-positive carriers were anti-HDV-positive [prevalence: 14.5% (95% confidence interval 11.1–17.8)]. The proportion of anti-HDV positive in HBsAg-positive patients was higher in intravenous drug users (44 of 104; 42.3%) than in MSM (seven of 213; 3.3%) or individuals infected heterosexually (six of 67; 9%) (P < 0.001). Likewise, the rate of anti-HDV in HBsAg-positive carriers was higher in southern (21%) and eastern Europe (25%) than in north (9%) and central Europe (11%) (P = 0.0032) (Fig. 1).

Fig. 1
Fig. 1:
Prevalence of antihepatitis delta virus antibody in serum hepatitis B virus surface antigen-positive patients in EuroSIDA.

Table 1 summarizes the main characteristics of the study population by HDV status. Most hepatitis delta patients in EuroSIDA were white (84%) and were receiving antiretroviral therapy at the time the study was conducted (67%), with a median CD4 cell count of 281 cells/μl (interquartile range, IQR: 184–389) and undetectable plasma HIV-RNA.

Table 1
Table 1:
Main characteristics of HIV-infected patients with chronic hepatitis B according to hepatitis delta status.

In comparison with anti-HDV-negative individuals, HBsAg-positive patients positive for anti-HDV were younger (median age, 34 vs. 38 years; P = 0.0007) and more frequently female (27.9 vs. 13.9%; P = 0.0056), intravenous drug users (72.1 vs. 16.6%; P < 0.0001), positive for anti-hepatitis C virus (HCV) (70.5 vs. 21.1%; P < 0.0001), lived in south and/or east Europe (52.4 vs. 26.6%; P < 0.0032) and were infected by HBV genotype D (50 vs. 12%; P < 0.01). In a multivariate analysis, however, the only independent predictor of anti-HDV-positive in HBsAg-positive carriers was intravenous drug use (odds ratio: 5.99; 95% confidence interval: 2.28–15.71; P = 0.0003).

HBV genotype distribution in anti-HDV-positive patients was as follows: D (50%), A (27%), AD (14%), AG (4.6%) and ADG (4.6%). By contrast, HBV genotypes in anti-HDV-negative patients were as follows: A (78%), D (12%), G (2.4%), F (1.6%), AD (1.6%), AG (1.6%), E (1.6%), F (1.6%) and C (1%).

For 38 individuals positive for anti-HDV, both serum HBV-DNA and HDV-RNA could be measured quantitatively. Both viruses were viraemic in 58%, only HDV viraemic in 29%, none had HBV exclusively viraemic and 13% were aviraemic for both viruses. Overall, 31 of 38 (86.8%) anti-HDV-positive patients had detectable serum HDV-RNA, with a median titer of 1.76 × 107 copies/ml (IQR: 2.59 × 103–8.89 × 109).

In anti-HDV-positive patients, an association was found between HBV genotype distribution and serum HBV-DNA levels. In patients with serum HBV-DNA more than 107 IU/ml, the only HBV genotype found was D, whereas in anti-HDV-negative patients, high levels of HBV-DNA were seen in up to 81% of HBV genotype A cases.

The proportion of individuals with detectable HBV viraemia was similar in patients with or without anti-HDV (59 vs. 63%, respectively; P = 0.54). However, the median serum HBV-DNA titer was significantly lower in anti-HDV-positive than in anti-HDV-negative patients (949 vs. 24 522 IU/ml, respectively; P = 0.003). Moreover, the proportion of patients with serum HBV-DNA above the upper limit of detection (>107 IU/ml) tended to be higher in anti-HDV-negative than in anti-HDV-positive patients (20 vs. 11%; P = 0.11).

Table 2 records the multivariate regression analysis in which factors associated with serum HBV-DNA levels were examined. Given that some antiretroviral agents (i.e. lamivudine, tenofovir or emtricitabine) also exert anti-HBV activity, their use was included in the model. Anti-HDV seropositivity together with positive and unknown HDV-RNA were associated with lower HBV-DNA. Likewise, HBV genotypes other than D were also associated with lower HBV-DNA levels while northern Europe was associated with higher HBV-DNA levels.

Table 2
Table 2:
Predictors of serum hepatitis B virus DNA levels.

A longitudinal analyses of HBsAg-positive patients in EuroSIDA allowed assessment of the proportion of patients that progressed to AIDS (31 events), to death (76 events), to AIDS and/or death (91 events) and to LRD (21 events). The median follow-up of the 422 HBsAg+ patients was 90.2 months (IQR 51.1–135.2). As shown in Table 3, anti-HDV positivity was significantly associated with death from any cause, progression to AIDS or death and progression to LRD, but not to progression to AIDS alone.

Table 3
Table 3:
Predictors of progression to AIDS, death or either in the serum hepatitis B virus surface antigen-positive, HIV study population.


The overall prevalence of anti-HDV in HIV-infected patients with chronic hepatitis B in EuroSIDA is 14.5%. Chronic hepatitis delta predominates in intravenous drug users, being present in up to 42% of those positive for HBsAg. The larger representation of intravenous drug users in south and east Europe in comparison with other regions explains that anti-HDV was particularly common in those geographical areas. Likewise, it explains the association between anti-HDV and anti-HCV positivity, as HCV is poorly transmitted sexually, whereas it is very efficiently acquired through parental routes [11].

More than 85% of anti-HDV patients in EuroSIDA exhibited detectable HDV viraemia in a single cross-sectional determination. It is worth mentioning that longitudinal testing most likely would have revealed circulating serum HDV-RNA in most of the remaining anti-HDV patients, as fluctuating levels of HDV-RNA and HBV-DNA are common in these individuals [12]. Viral interference between HBV and HDV is well known [12,13]. Interestingly, in our study it was particularly recognized in HBV genotype A patients superinfected with HDV, whereas overt coreplication of HBV and HDV was more common in HBV genotype D carriers. Hypothetically, this last group of patients replicating both HBV and HDV might experience enhanced liver damage [14]. This differential effect of HDV superinfection on the replication of distinct HBV variants has been noticed for some lamivudine-resistant HBV mutants which impair HDV replication compromising viral secretion [15]. Our findings suggest that viral interference between HDV and HBV might be more frequent over HBV genotype A than D. A more limited production of HBsAg by HBV genotype A than D might contribute to explain this observation. In our study, we did not record information on Hepatitis B e antigen (HBeAg) which is associated with greater serum HBsAg levels [16,17] and is more frequently positive in adults infected by HBV genotype A than D [12].

Treatment of chronic hepatitis delta is a huge challenge [18]. HDV replicates using a human hepatocyte polymerase; so, nucleos(t)ide analogues designed to act as inhibitory competitors of viral polymerases do not block HDV replication directly. Current recommended therapy for chronic hepatitis delta consists of the administration of pegylated interferon-α for at least 12 months [19,20]. Future therapeutic options may include prenylate inhibitors [21]. In the meantime, several reports have highlighted that potent nucleos(t)ide analogues such as tenofovir may be beneficial in a subset of patients with delta hepatitis, as they may experience normalization of liver enzymes, reduction or negativization of HDV-RNA and even clearance and/or seroconversion of serum HBsAg [22,23]. Similar results have not been obtained using other nucleos(t)ide analogues, such as lamivudine [24] or adefovir [20]. The potential benefit of tenofovirin delta hepatitis, however, has been mainly limited to HBV genotype A and/or HBeAg-positive carriers. Although the underlying reason for it remains unclear, a reduced production and availability of the HBsAg protein in HBV genotype A patients compared with other HBV genotypes, such as D, might explain why potent suppressors of HBV replication might impair HDV production in some HBV variants preferentially than in others. HBsAg production and HBV replication breaks down in patients with HBeAg-negative chronic hepatitis B, when a growing proportion of HBsAg becomes to be produced from HBV genomes integrated in the host chromosomes instead of from nonintegrated cccDNA in hepatocytes [16]. Although we did not record HBeAg in our patient population, it is reasonable to assume that HBeAg-negative would have been more frequent in HBV genotype D than A, in line with observations from others [12].

Our study has several limitations. We already mentioned above that HBeAg was not recorded in our study population, and that it may have influenced indirectly the association found between HBV genotypes and serum HDV-RNA levels. Another limitation of our study was that HDV markers were examined in only a fraction of HBsAg-positive carriers. Overall 422 of 1319 (32%) individuals that had ever reported serum HBsAg-positive in EuroSIDA were tested for anti-HDV antibodies, given that no stored sera were available for the rest at the time they were HBsAg-positive. Even so, the number of patients positive for anti-HDV antibodies in our study (61) is one of the largest that has been characterized virologically so far. Moreover, we are confident about the representativeness of our patient population, because in a study conducted in Spain over 37 delta hepatitis patients negative for HIV [12], the proportion of viraemic patients for either HBV and/or HDV was comparable to ours, although there was a trend for a greater rate of dually viraemic individuals in our HIV population than in that HIV-negative series (58% vs. 40%, respectively). Hypothetically, immunodeficiency might ameliorate viral interference phenomena that characterize multiple viral hepatitis co-infections, allowing concomitant replication of multiple viruses [25,26].

Most guidelines recommend that all HBsAg-positive patients should be tested for anti-HDV antibodies [27–29]. Given that a fraction of HDV-seropositive individuals may not actively replicate the virus, serum HDV-RNA should be measured and treatment be considered in patients with detectable viraemia, given that chronic hepatitis delta is associated with a high risk of cirrhosis in HIV-infected patients [30]. Moreover, in our study we reported for the first time that hepatitis delta was further predictive of increased risk of LRD and overall mortality in HIV patients. Failure to exclude HDV infection in HBsAg carriers may result in an unexpected worse outcome and trigger unnecessary search for other causes of liver disease.


V.S., J.R., J.L. and L.P. designed the study; E.P. and V.S. were responsible for the virological analyses; D.G. did the statistical analyses; V.S., J.R., L.P., J.L., A.dA.M., A.H., C.L., F.A. and S.d.W. helped to collect laboratory and clinical information and reviewed the article.

Conflicts of interest

There are no conflicts of interest.


1. Hughes S, Wedemeyer H, Harrison P. Hepatitis delta virus. Lancet 2011; 378:73–85.
2. Wedemeyer H, Manns M. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7:31–40.
3. Rizzetto M. Hepatitis D: thirty years after. J Hepatol 2009; 50:1043–1050.
4. Abbas Z, Jafri W, Raza S. Hepatitis D: scenario in the Asia-Pacific region. World J Gastroenterol 2010; 16:554–562.
5. Wedemeyer H, Heidrich B, Manns M. Hepatitis D virus infection: not a vanishing disease in Europe. Hepatology 2007; 45:1331–1332.
6. Kucirka L, Farzadegan H, Field J, Mehta S, Winters M, Glenn J, et al. Prevalence, correlates, and viral dynamics of hepatitis delta among injecting drug users. J Infect Dis 2010; 202:845–852.
7. Mocroft A, Ledergerber B, Katlama C, Kirk O, Reiss P, d’Arminio Monforte A, et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 2003; 362:22–29.
8. Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katlama C, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005; 19:593–601.
9. Soriano V, Mocroft A, Peters L, Rockstroh J, Antunes F, Kirkby N, et al. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. J Antimicrob Chemother 2010; 65:548–555.
10. Le Gal F, Gordien E, Affolabi D, Hanslik T, Alloui C, Deny P, et al. Quantification of hepatitis delta virus RNA in serum by consensus real-time PCR indicates different patterns of virological response to interferon therapy in chronically infected patients. J Clin Microbiol 2005; 43:2363–2369.
11. Rockstroh J, Mocroft A, Soriano V, Tural C, Losso M, Horban A, et al. Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis 2005; 192:992–1002.
12. Schaper M, Rodriguez-Frias F, Jardi R, Tabernero D, Homs M, Ruiz G, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol 2010; 52:658–664.
13. Morsica G, Bagaglio S, Cicconi P, Capobianchi M, Pellizzer G, Caramello P, et al. Viral interference between hepatitis B, C, and D viruses in dual and triple infections in HIV-positive patients. J Acquir Immune Defic Syndr 2009; 51:574–581.
14. Wedemeyer H. Re-emerging interest in hepatitis delta: new insights into the dynamic interplay between HBV and HDV. J Hepatol 2010; 52:627–629.
15. Vietheer P, Netter H, Sozzi T, Bartholomeusz A. Failure of the lamivudine-resistant rtM204I hepatitis B mutants to efficiently support hepatitis delta virus secretion. J Virol 2005; 79:6570–6573.
16. Thompson A, Nguyen T, Iser D, Ayres A, Jackson K, Littlejohn M, et al. Serum HBsAg and HBeAg titers: disease phase influences correlation with viral load and intrahepatic HBV markers. Hepatology 2010; 51:1933–1944.
17. Sonneveld M, Zoutendijk R, Janssen H. Hepatitis B surface antigen monitoring and management of chronic hepatitis B. J Viral Hepat 2011; 18:449–457.
18. Ciancio A, Rizzetto M. Peg-IFN for the treatment of hepatitis D. Nat Rev Gastroenterol Hepatol 2011; 8:304–306.
19. Farci P, Mandas A, Coiana A, Lai M, Desmet V, Van Eyken P, et al. Treatment of chronic hepatitis D with interferon-α 2a. N Engl J Med 1994; 330:88–94.
20. Wedemeyer H, Yurdaydin C, Dalekos G, Erhardt A, Çakaloglu Y, Degertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364:322–331.
21. Bordier B, Ohkanda J, Liu P, Lee S, Salazar F, Marion P, et al. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus. J Clin Invest 2003; 112:407–414.
22. Sheldon J, Ramos B, Toro C, Rios P, Martinez-Alarcon J, Bottecchia M, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?. Antivir Ther 2008; 13:97–102.
23. Martín-Carbonero L, Teixeira T, Poveda E, Plaza Z, Vispo E, Soriano V. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS 2011; 25:73–79.
24. Yurdaydin C, Bozkaya H, Onder F, Sentürk H, Karaaslan H, Akdoğan M, et al. Treatment of chronic delta hepatitis with lamivudine vs. lamivudine + interferon vs. interferon. J Viral Hepat 2008; 15:314–321.
25. García-Samaniego J, Soriano V, Bravo R, González-Lahoz J, Muñoz F. Viral replication in patients with multiple hepatitis virus infections. Gastroenterology 1994; 107:322–323.
26. Boyd A, Lacombe K, Miailhes P, Gozlan J, Bonnard P, Molina JM, et al. Longitudinal evaluation of viral interactions in treated HIV-hepatitis B co-infected patients with additional hepatitis C and D virus. J Viral Hepat 2010; 17:65–76.
27. EASL. Clinical practice guidelines: management of chronic hepatitis. B. J Hepatol 2009; 50:227–242.
28. Soriano V, Puoti M, Peters M, Benhamou Y, Sulkowski M, Zoulim F, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008; 22:1399–1410.
29. Rockstroh J, Bhagani S, Benhamou Y, Bruno R, Mauss S, Peters L, et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med 2008; 9:82–88.
30. Castellares C, Barreiro P, Martín-Carbonero L, Labarga P, Vispo ME, Casado R, et al. Liver cirrhosis in HIV-infected patients: prevalence, etiology and clinical outcome. J Viral Hepat 2008; 15:165–172.

EuroSIDA; hepatitis delta; HIV; liver

© 2011 Lippincott Williams & Wilkins, Inc.